Literature DB >> 28974092

Poly(I:C)-Encapsulating Nanoparticles Enhance Innate Immune Responses to the Tuberculosis Vaccine Bacille Calmette-Guérin (BCG) via Synergistic Activation of Innate Immune Receptors.

Martin T Speth1, Urska Repnik1, Elisabeth Müller1,2, Julia Spanier3, Ulrich Kalinke3, Alexandre Corthay2, Gareth Griffiths1.   

Abstract

The attenuated live vaccine strain bacille Calmette-Guérin (BCG) is currently the only available vaccine against tuberculosis (TB), but is largely ineffective against adult pulmonary TB, the most common disease form. This is in part due to BCG's ability to interfere with the host innate immune response, a feature that might be targeted to enhance the potency of this vaccine. Here, we investigated the ability of chitosan-based nanoparticles (pIC-NPs) containing polyinosinic-polycytidylic acid (poly(I:C)), an inducer of innate immunity via Toll-like receptor 3 (TLR3), to enhance the immunogenicity of BCG in mouse bone marrow derived macrophages (BMDM) in vitro. Incorporation of poly(I:C) into NPs protected it against degradation by ribonucleases and increased its uptake by mouse BMDM. Whereas soluble poly(I:C) was ineffective, pIC-NPs strongly enhanced the proinflammatory immune response of BCG-infected macrophages in a synergistic fashion, as evident by increased production of cytokines and induction of nitric oxide synthesis. Using macrophages from mice deficient in key signaling molecules involved in the pathogen recognition response, we identified combined activation of MyD88- and TRIF-dependent TLR signaling pathways to be essential for the synergistic effect between BCG and NP. Moreover, synergy was strongly dependent on the order of the two stimuli, with TLR activation by BCG functioning as the priming event for the subsequent pIC-NP stimulus, which acted through an auto-/paracrine type I interferon (IFN) feedback loop. Our results provide a foundation for a promising new approach to enhance BCG-vaccine immunogenicity by costimulation with NPs. They also contribute to a molecular understanding of the observed synergistic interaction between the pIC-NPs and BCG vaccine.

Entities:  

Keywords:  Toll-like receptor synergy; adjuvant; bacille Calmette−Guérin (BCG); chitosan; nanoparticles; poly(I:C); type I interferons (IFNs)

Mesh:

Substances:

Year:  2017        PMID: 28974092     DOI: 10.1021/acs.molpharmaceut.7b00795

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  12 in total

Review 1.  Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.

Authors:  Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 2.  Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.

Authors:  Erica Stewart; James A Triccas; Nikolai Petrovsky
Journal:  Microorganisms       Date:  2019-08-12

Review 3.  RNA Sensing of Mycobacterium tuberculosis and Its Impact on TB Vaccination Strategies.

Authors:  Sanne Burkert; Ralf R Schumann
Journal:  Vaccines (Basel)       Date:  2020-02-04

Review 4.  Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development.

Authors:  Samuel T Pasco; Juan Anguita
Journal:  Cells       Date:  2020-09-16       Impact factor: 6.600

5.  High Immunogenicity of a T-Cell Epitope-Rich Recombinant Protein Rv1566c-444 From Mycobacterium tuberculosis in Immunized BALB/c Mice, Despite Its Low Diagnostic Sensitivity.

Authors:  Xiuli Luan; Xueting Fan; Ruihuan Wang; Yunli Deng; Zixin Chen; Na Li; Yuhan Yan; Xiaoyan Li; Haican Liu; Guilian Li; Kanglin Wan
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

6.  Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.

Authors:  Elisabeth Müller; Martin Speth; Panagiotis F Christopoulos; Anna Lunde; Ajna Avdagic; Inger Øynebråten; Alexandre Corthay
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

Review 7.  Nanoparticle Vaccines Against Infectious Diseases.

Authors:  Rashmirekha Pati; Maxim Shevtsov; Avinash Sonawane
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

8.  The adjuvant G3 promotes a Th1 polarizing innate immune response in equine PBMC.

Authors:  Stina Hellman; Bernt Hjertner; Bror Morein; Caroline Fossum
Journal:  Vet Res       Date:  2018-10-22       Impact factor: 3.683

9.  Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection.

Authors:  Juan Manuel Coya; Laura De Matteis; Alexandre Giraud-Gatineau; Anne Biton; Inés Serrano-Sevilla; Anne Danckaert; Marie-Agnès Dillies; Brigitte Gicquel; Jesus M De la Fuente; Ludovic Tailleux
Journal:  J Nanobiotechnology       Date:  2019-01-25       Impact factor: 10.435

Review 10.  Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis.

Authors:  Reginaldo G Bastos; Heba F Alzan; Vignesh A Rathinasamy; Brian M Cooke; Odir A Dellagostin; Raúl G Barletta; Carlos E Suarez
Journal:  Vaccines (Basel)       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.